Zynerba Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Armando Anido

최고 경영자

US$1.9m

총 보상

CEO 급여 비율	33.6%
CEO 임기	9yrs
CEO 소유권	1.9%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	8.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Armando Anido 의 보수는 Zynerba Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$633k	-US$35m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	US$2m	US$603k	-US$37m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$1m	US$585k	-US$51m
Sep 30 2020	n/a	n/a	-US$52m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$36m
Dec 31 2019	US$1m	US$568k	-US$33m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$2m	US$568k	-US$40m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$41m
Mar 31 2018	n/a	n/a	-US$37m
Dec 31 2017	US$2m	US$552k	-US$32m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$26m
Dec 31 2016	US$901k	US$536k	-US$23m

보상 대 시장: Armando 의 총 보상 ($USD 1.88M )은 German 시장( $USD 472.15K ).

보상과 수익: Armando 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Armando Anido (65 yo)

9yrs

테뉴어

US$1,881,402

보상

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% € 1.2m
Terri Sebree	President	9yrs	US$1.38m	1.18% € 730.3k
James Fickenscher	CFO & VP of Corporate Development (Leave of Absence)	7.1yrs	US$1.26m	0.75% € 463.1k
Kenneth Jones	VP, Corporate Controller & Interim CFO	6.6yrs	데이터 없음	0.17% € 104.7k
Albert Parker	Chief Legal Officer & Corporate Secretary	1.7yrs	데이터 없음	0.45% € 278.1k
Joseph Apostolico	Vice President of Human Resources	5.6yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 6ZY 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% € 1.2m
Kenneth Moch	Independent Director	8.2yrs	US$107.50k	0.15% € 92.8k
Daniel Kisner	Independent Director	8.2yrs	US$105.00k	0.15% € 92.8k
Warren Cooper	Lead Independent Director	8.2yrs	US$135.00k	0.15% € 92.8k
John Butler	Independent Director	5.5yrs	US$102.50k	0.16% € 98.9k
William Federici	Independent Director	8.2yrs	US$110.00k	0.15% € 92.8k
Steven Siegel	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Randi Hagerman	Member of Scientific Advisory Board	8yrs	데이터 없음	데이터 없음
Elizabeth Berry-Kravis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nicole Tartaglia	Member of Scientific Advisory Board	7yrs	데이터 없음	데이터 없음
Pamela Stephenson	Independent Director	4.7yrs	US$100.00k	0.15% € 92.8k
Craig Erikson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

8.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 6ZY 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.

Zynerba Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Insufficient new directors

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: €4.07

New 90-day low: €2.69

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

New 90-day high: €3.33

New 90-day low: €2.80

Zynerba Pharmaceuticals, Inc. Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

First half earnings released

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell Small Cap Completeness Index

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell 3000 Growth Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령